Data as of Apr 15
 -0.04 / -0.16%
Today’s Change
Today|||52-Week Range
Health Technology

Company Description

TESARO, Inc. is an oncology-focused biopharmaceutical company. It is dedicated to improving the lives of cancer patients. The company's product portfolio currently consists of three oncology-related product candidates: Rolapitant, a potent and long-acting neurokinin-1, receptor antagonist currently in phase 3 clinical trials for the prevention of chemotherapy induced nausea and vomiting; Niraparib, formerly known as MK-4827, is an orally active and potent poly polymerase, inhibitor that has undergone a phase 1 clinical trial in cancer patients as a monotherapy and is currently under evaluation by Merck & Co., Inc., for use in combination with temozolomide for the treatment of solid tumors; and TSR-011, an orally available anaplastic lymphoma kinase, inhibitor currently in preclinical development. These product candidates intend to make them available to cancer patients in North America, Europe and China through its commercialization efforts and to establish a network of licensees and distributors in other geographic areas. It plans to test TSR-011 in clinical trials as a treatment for non-small cell lung cancer, and potentially other cancer indications. TESARO was founded by Leon Moulder, Jr., Mary Lynne Hedley and Richard J. Rodgers on March 26, 2010 and is headquartered in Waltham, MA.

Contact Information

1000 Winter Street
Waltham Massachusetts 02451
P:(339) 970-0900
Investor Relations:
(781) 325-1116



Individual stakeholders48.03%
Mutual fund holders25.86%
Other institutional21.28%

Top Executives

Leon O. MoulderChief Executive Officer & Director
Mary Lynne HedleyPresident, Director & Chief Scientific Officer
Edward C. EnglishChief Financial Officer, VP & Controller
Robert E. MartellChief Medical Officer
Jennifer DavisSenior Director-Investor Relations

To view my watchlist

Not a member yet?

Sign up now for a free account
Market indexes are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer LIBOR Warning: Neither BBA Enterprises Limited, nor the BBA LIBOR Contributor Banks, nor Reuters, can be held liable for any irregularity or inaccuracy of BBA LIBOR. Disclaimer. Morningstar: © 2014 Morningstar, Inc. All Rights Reserved. Disclaimer The Dow Jones IndexesSM are proprietary to and distributed by Dow Jones & Company, Inc. and have been licensed for use. All content of the Dow Jones IndexesSM © 2014 is proprietary to Dow Jones & Company, Inc. Chicago Mercantile Association. The market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. FactSet Research Systems Inc. 2014. All rights reserved. Most stock quote data provided by BATS.